Adverse events · people with cardiac channelopathies
Implantable cardioverter defibrillators showed no clear difference in adverse events compared with β‐blocker therapy (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · people with cardiac channelopathies
Implantable cardioverter defibrillators may leads to higher non‐fatal cardiovascular events compared with β‐blocker therapy (low certainty).
1 finding from 1 review
ICD, inappropriate shock ( · people with cardiac channelopathies
Implantable cardioverter defibrillators may leads to higher inappropriate ICD firing compared with β‐blocker therapy (low certainty).
1 finding from 1 review
All‐cause mortality · patients with heart failure
Coenzyme Q10 probably leads to lower all‐cause mortality compared with placebo or conventional therapy (moderate certainty).
1 finding from 1 review
Myocardial infarction · patients with heart failure
Coenzyme Q10 showed no clear difference in myocardial infarction compared with placebo or conventional therapy (low certainty).
1 finding from 1 review
Stroke · patients with heart failure
Coenzyme Q10 showed no clear difference in stroke compared with placebo or conventional therapy (low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with heart failure
Coenzyme Q10 probably leads to lower hospitalisation for heart failure compared with placebo or conventional therapy (moderate certainty).
1 finding from 1 review
Left ventricular ejection fraction (%) · patients with heart failure
1 finding from 1 review
Exercise capacity · patients with heart failure
1 finding from 1 review
Adverse events · patients with heart failure
Coenzyme Q10 showed no clear difference in adverse events compared with placebo or conventional therapy (low certainty).
1 finding from 1 review
Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation probably leads to lower all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (low certainty).
1 finding from 1 review
Minor haemorrhage · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (low certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (moderate certainty).
1 finding from 1 review
Minor haemorrhage · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (low certainty).
1 finding from 1 review
Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (low certainty).
1 finding from 1 review